−0.3285EUR
−8.45 MEUR
102.00 KEUR
38.92 M
About CELYAD ONCOLOGY SA
Sector
Industry
CEO
Michel E. Lussier
Website
Headquarters
Mont-Saint-Guibert
Employees (FY)
17
Founded
2007
ISIN
BE0974260896
FIGI
BBG005D7KHD4
Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on TURQUOISE exchange CELYAD ONCOLOGY SA stocks are traded under the ticker CYADB.
CELYAD ONCOLOGY SA is going to release the next earnings report on Sep 20, 2024. Keep track of upcoming events with our Earnings Calendar.
CYADB earnings for the last quarter are −0.62 EUR whereas the estimation was −0.97 EUR which accounts for 36.37% surprise. Estimated earnings for the next quarter are −0.80 EUR. See more details about CELYAD ONCOLOGY SA earnings.
CELYAD ONCOLOGY SA revenue for the last quarter amounts to 0 EUR despite the estimated figure of 0 EUR. In the next quarter revenue is expected to reach 2.25 M EUR.
Yes, you can track CELYAD ONCOLOGY SA financials in yearly and quarterly reports right on TradingView.
CYADB net income for the last quarter is −4.71 M EUR, while the quarter before that showed −3.74 M EUR of net income which accounts for −25.88% change. Track more CELYAD ONCOLOGY SA financial stats to get the full picture.
No, CYADB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, CYADB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CELYAD ONCOLOGY SA stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 17.00 employees. See our rating of the largest employees — is CELYAD ONCOLOGY SA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CELYAD ONCOLOGY SA EBITDA is −9.82 M EUR, and current EBITDA margin is −9.61 K%. See more stats in CELYAD ONCOLOGY SA financial statements.